The 2023 ACR/EULAR aPS classification criteria include an entry criterion of at least one positive aPL test within 3 years of identification of an aPL-associated clinical criterion, followed by six additive clinical criteria (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and two laboratory criteria (lupus anticoagulant [LAC] functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin [aCL] and/or IgG/IgM anti–β2-glycoprotein 1 antibodies [aβ2GP1]). This evidence concerns the gene CD40LG and Arterial thrombosis.